SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Higuchi Ichiyō Synthetic CCD

PatientHiguchi Ichiyō
Date of birth2002-05-02
IdentifiersMRN HR-NI029-SYN; SSN (made up) 000-29-5108
Document date2026-11-01
AuthorAiko Lindgren-Tanaka, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for seven weeks of cough, fevers, night sweats and weight loss: chest X-ray, sputum specimens, blood tests, airborne precautions, and a report of suspected tuberculosis to the public health center. Concerns: She has coughed for weeks, sweats at night and has lost weight, and fears it is tuberculosis; She supports her household by writing and cannot afford to stop working or to pay for many tests; She is afraid of passing the illness to the people she lives with and of what neighbors and editors will think. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 100 mg tablets, two tablets (200 mg) daily200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route2026-04-17 to 2026-10-15completedS
Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeksOral route2026-04-17 to 2026-10-15completedS
Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phaseOral route2026-04-17 to 2026-06-11completedS
Ethambutol 100 mg tablets, six tablets (600 mg) daily600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results returnOral route2026-04-17 to 2026-05-22stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route2026-04-17 to 2026-10-15completedS
Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule twice daily with food for five daysOne capsule twice daily with food for five daysOral route2026-07-20 to 2026-07-24completedS

Procedures

ProcedureDatesStatusEvidence
Chest X-ray, two views: patchy opacities in the apical and posterior segments of the right upper lobe with small nodules; no cavity, effusion or hilar enlargement2026-04-14 to 2026-04-14completedS
Chest X-ray, two views, at the end of treatment: right upper lobe opacities cleared, leaving a few linear scars; kept as the baseline for any future comparison2026-10-20 to 2026-10-20completedS
Cervical cytology (Papanicolaou test), first screening2026-08-24 to 2026-08-24completedS
Advance care planning conversation, about 16 minutes2026-08-24 to 2026-08-24completedS

Immunizations

DateVaccineStatusEvidence
2026-08-24Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)completedS
2026-08-24Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
2026-08-24Human papillomavirus 9-valent vaccine, dose 1 of 3completedS
2026-10-20Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS
2026-10-20Human papillomavirus 9-valent vaccine, dose 2 of 3completedS
2026-10-20Influenza vaccine, inactivated, trivalent, preservative-freecompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

No historical medical events are recorded.

Family History

RelativeConditionAge at deathEvidence
fatherDied of illness in 1889; cause not recorded in the cited sourceD (CLM-0004)

Health Concerns

ConcernStatusEvidence
She has coughed for weeks, sweats at night and has lost weight, and fears it is tuberculosisactiveS
She supports her household by writing and cannot afford to stop working or to pay for many testsactiveS
She is afraid of passing the illness to the people she lives with and of what neighbors and editors will thinkactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 13.2 on 2026-10-20; Leukocytes [#/volume] in Blood by Automated count 8.6 on 2026-04-14; Platelets [#/volume] in Blood by Automated count 452 on 2026-04-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 on 2026-10-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 2026-10-20; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 2026-06-12; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 74 on 2026-04-14; Albumin [Mass/volume] in Serum or Plasma 4.2 on 2026-10-20; Creatinine [Mass/volume] in Serum or Plasma 0.56 on 2026-04-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 131 on 2026-04-14; Glucose [Mass/volume] in Serum or Plasma 82 on 2026-04-14; Hemoglobin A1c/Hemoglobin.total in Blood 5.1 on 2026-04-14; Visual acuity uncorrected Right eye by ETDRS eye chart 85 on 2026-06-12; Visual acuity uncorrected Left eye by ETDRS eye chart 85 on 2026-06-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-10-20; Total score [AUDIT-C] 0 on 2026-08-24; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-08-24; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 4 on 2026-08-24 [S]

Strengths and supports: Supports and strengths she names: her writing, her readers and editors, and the poetry she studied when young [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and cultureresolvedconfirmed R05.3S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D).
Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected)resolvedconfirmed A15.0S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic.
Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dLresolvedconfirmed E44.0S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty.
Low and irregular income from writing, with a household to support; costs of care are a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented poverty and household responsibilities.
Acute uncomplicated cystitis, treated with nitrofurantoin rather than a fluoroquinolone during tuberculosis treatment; resolvedresolvedconfirmed N30.00S — Synthetic intercurrent illness; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-14Hemoglobin [Mass/volume] in Blood11.4g/dL12-15.5 g/dLLowS
2026-04-14Leukocytes [#/volume] in Blood by Automated count8.610*3/uL4-11 10*3/uLNormalS
2026-04-14Platelets [#/volume] in Blood by Automated count45210*3/uL150-400 10*3/uLHighS
2026-04-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma12U/L7-35 U/LNormalS
2026-04-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L10-35 U/LNormalS
2026-04-14Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
2026-04-14Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma74U/L35-104 U/LNormalS
2026-04-14Albumin [Mass/volume] in Serum or Plasma3.3g/dL3.5-5 g/dLLowS
2026-04-14Creatinine [Mass/volume] in Serum or Plasma0.56mg/dL0.5-1 mg/dLNormalS
2026-04-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M131mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-14Glucose [Mass/volume] in Serum or Plasma82mg/dL70-99 mg/dLNormalS
2026-04-14Hemoglobin A1c/Hemoglobin.total in Blood5.1%Below 5.7% is normal; 6.5% or more is diabetesNormalS
2026-04-14Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
2026-04-14Visual acuity uncorrected Left eye by ETDRS eye chart85{letters}>=80NormalS
2026-04-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
2026-04-14Total score [AUDIT-C]0{score}S
2026-05-01Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-35 U/LNormalS
2026-05-01Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L10-35 U/LNormalS
2026-05-01Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-05-01Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
2026-05-01Visual acuity uncorrected Left eye by ETDRS eye chart84{letters}>=80NormalS
2026-06-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-35 U/LNormalS
2026-06-12Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma25U/L10-35 U/LNormalS
2026-06-12Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-06-12Albumin [Mass/volume] in Serum or Plasma3.8g/dL3.5-5 g/dLNormalS
2026-06-12Hemoglobin [Mass/volume] in Blood12.4g/dL12-15.5 g/dLNormalS
2026-06-12Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
2026-06-12Visual acuity uncorrected Left eye by ETDRS eye chart85{letters}>=80NormalS
2026-06-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-10-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
2026-10-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L10-35 U/LNormalS
2026-10-20Albumin [Mass/volume] in Serum or Plasma4.2g/dL3.5-5 g/dLNormalS
2026-10-20Hemoglobin [Mass/volume] in Blood13.2g/dL12-15.5 g/dLNormalS
2026-10-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-08-24Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-08-24Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]4{score}S
2026-08-24Total score [AUDIT-C]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-04-14Body height148cmS
2026-04-14Body weight38.5kgS
2026-04-14Body mass index (BMI) [Ratio]17.6kg/m2S
2026-04-14Systolic blood pressure98mm[Hg]S
2026-04-14Diastolic blood pressure62mm[Hg]S
2026-04-14Heart rate104/minS
2026-04-14Respiratory rate20/minS
2026-04-14Body temperature37.8CelS
2026-04-14Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-04-17Body height148cmS
2026-04-17Body weight38.4kgS
2026-04-17Body mass index (BMI) [Ratio]17.5kg/m2S
2026-04-17Systolic blood pressure96mm[Hg]S
2026-04-17Diastolic blood pressure60mm[Hg]S
2026-04-17Heart rate100/minS
2026-04-17Respiratory rate20/minS
2026-04-17Body temperature37.6CelS
2026-04-17Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-05-01Body height148cmS
2026-05-01Body weight39.2kgS
2026-05-01Body mass index (BMI) [Ratio]17.9kg/m2S
2026-05-01Systolic blood pressure100mm[Hg]S
2026-05-01Diastolic blood pressure62mm[Hg]S
2026-05-01Heart rate90/minS
2026-05-01Respiratory rate18/minS
2026-05-01Body temperature37.1CelS
2026-05-01Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-06-12Body height148cmS
2026-06-12Body weight41kgS
2026-06-12Body mass index (BMI) [Ratio]18.7kg/m2S
2026-06-12Systolic blood pressure102mm[Hg]S
2026-06-12Diastolic blood pressure64mm[Hg]S
2026-06-12Heart rate80/minS
2026-06-12Respiratory rate16/minS
2026-06-12Body temperature36.8CelS
2026-06-12Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-20Body height148cmS
2026-10-20Body weight44kgS
2026-10-20Body mass index (BMI) [Ratio]20.1kg/m2S
2026-10-20Systolic blood pressure106mm[Hg]S
2026-10-20Diastolic blood pressure68mm[Hg]S
2026-10-20Heart rate72/minS
2026-10-20Respiratory rate14/minS
2026-10-20Body temperature36.5CelS
2026-10-20Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-07-20Body height148cmS
2026-07-20Body weight42kgS
2026-07-20Body mass index (BMI) [Ratio]19.2kg/m2S
2026-07-20Systolic blood pressure104mm[Hg]S
2026-07-20Diastolic blood pressure66mm[Hg]S
2026-07-20Heart rate84/minS
2026-07-20Respiratory rate16/minS
2026-07-20Body temperature37CelS
2026-07-20Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-08-24Body height148cmS
2026-08-24Body weight42.6kgS
2026-08-24Body mass index (BMI) [Ratio]19.4kg/m2S
2026-08-24Systolic blood pressure104mm[Hg]S
2026-08-24Diastolic blood pressure66mm[Hg]S
2026-08-24Heart rate76/minS
2026-08-24Respiratory rate14/minS
2026-08-24Body temperature36.6CelS
2026-08-24Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-04-14New patient visit for seven weeks of cough, fevers, night sweats and weight loss: chest X-ray, sputum specimens, blood tests, airborne precautions, and a report of suspected tuberculosis to the public health centerfinishedS
2026-04-17Results visit: pulmonary tuberculosis confirmed; infectious diseases consultation and the start of the standard six-month regimenfinishedS
2026-05-01Two-week review on treatment: culture result, liver tests, vision, and release from precautionsfinishedS
2026-06-12End of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phasefinishedS
2026-10-20End-of-treatment review after 182 dosesfinishedS
2026-07-20Same-day sick visit for acute cystitis during tuberculosis treatmentfinishedS
2026-08-24Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Diagnosis and safety: chest X-ray; three sputum specimens at least eight hours apart, one early in the morning, for acid-fast smear, Xpert MTB/RIF Ultra, liquid and solid culture and drug susceptibility testing; HIV, hepatitis B and hepatitis C tests and a pregnancy test; blood count, liver and kidney tests, glucose and hemoglobin A1c; visual acuity and color vision before ethambutolcompletedGL-ATS-TBDX-2017, GL-ATS-TB-2016, GL-WHO-TB-2022S
Infectious diseases consultation at the results visit to confirm the diagnosis, choose between the six-month and four-month regimens, set the doses for her weight, and plan monitoring and infection controlcompletedGL-ATS-TB-2016, GL-ATS-TB-2025, GL-CDC-4MO-2022S
Infection control and public health: airborne precautions in the clinic; at home, no visitors, a surgical mask in shared rooms, windows open, and sleeping in her own room until the public health center confirms she is no longer infectious; report of suspected tuberculosis to the public health center the same day and notification at once on diagnosis; a contact investigation of her household and other close contacts led by the public health centercompletedGL-MHLW-TB-NOTIFY, GL-CDC-CONTACT-2005, GL-ATS-TB-2016S
Nutrition, income and writing: two dietitian visits in the first month, three meals and two energy-dense snacks a day with two oral nutrition supplement drinks, and weight at every visit; a medical social worker to apply for public funding of tuberculosis treatment and to review other help with costs; a paced writing plan of short sessions in daylight with rest; PHQ-9 at intake, at two months and at the end of treatmentcompletedGL-ASPEN-MALN-2012, GL-JP-TB-FUNDING, GL-USPSTF-DEP-2023S
Treatment: isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg and ethambutol 600 mg daily for eight weeks, then isoniazid and rifampin daily for eighteen weeks, with pyridoxine 50 mg, by daily video-observed therapy with the public health center; ethambutol stopped once the isolate is susceptible to isoniazid and rifampin; liver tests at two weeks and monthly in the intensive phase because of her low weight and albumin; visual acuity and color vision monthly while on ethambutol; sputum smear and culture at two weeks and two months; chest X-ray at the end of treatmentcompletedGL-ATS-TB-2016, GL-ATS-TB-2025, GL-WHO-TB-2022, GL-ATS-HEPATOTOX-2006S
Acute cystitis: nitrofurantoin 100 mg twice daily for five days with urine culture; no fluoroquinolone, because these drugs are kept for drug-resistant tuberculosis and can blur the picture of tuberculosis; continue every tuberculosis dose; plenty of fluids; return for fever, flank pain, vomiting or symptoms that are not better in two dayscompletedGL-IDSA-UTI-2010, GL-ATS-TB-2016S
Prevention: cervical cytology now and every three years; Tdap; hepatitis B vaccine in two doses and HPV vaccine in three doses; influenza vaccine in the autumn; folic acid 0.4 mg daily advised; contraception counseling that rifampin makes hormonal pills, patches, rings and implants unreliable, with a copper IUD, injectable progestin or condoms as reliable choices if she needs contraception during treatmentcompletedGL-USPSTF-CERV-2018, GL-CDC-IMZ-2026, GL-CDC-SPR-2024, GL-USPSTF-FOLIC-2023S

Goals

GoalTargetStatusOutcomeProvenance
Complete 182 daily doses within about six and a half months by video-observed therapy2026-10-20completedAll 182 doses completed in 26 weeks: 56 in the intensive phase and 126 in the continuation phase, none missedS
Sputum culture negative at two months2026-10-20completedThe cultures taken at two weeks and at two months both showed no growth after six weeksS
Weight at least 44 kg (BMI about 20) by the end of treatment2026-10-20completed44.0 kg at the end of treatment, from 38.5 kg at intakeS
Keep writing on a paced schedule without losing income during treatment2026-10-20completedPublic funding covered most treatment costs; she kept writing about two hours a day and finished new workS
No drug-induced liver injury or loss of vision during treatment2026-10-20completedLiver tests normal throughout; visual acuity unchangedS

Functional Status

Mental Status